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allogeneic transfusion ($1512), autologous ($1899) and allogeneic transfusion
($1906) with differences persisting in sensitivity analyses. Cell salvage resulted in
net savings at a threshold of $556/patient. CONCLUSIONS:Use of CS, particularly
with autologous blood pre-donation appears cost-saving and cost-effective in pe-
diatric surgery and should be encouraged.
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OBJECTIVES: Surgical site infections (SSIs) associated with total knee arthroplasty
(TKA) have a significant negative impact on outcomes and hospital reimburse-
ment. Our study uniquely looks at the impact of patients having SSI in their initial
admissionwith downstream outcomes of readmission to assess the complete con-
sequences of TKA related SSI, beyond a single episode of care. METHODS: Thom-
son Medstat Marketscan® Database was used to identify patients having a TKA
(ICD9-CM procedure code 81.54) between January 2007 and December 2009. Pa-
tients experiencing infections were defined by ICD-9-CM codes 998.5x, 998.66 and
998.67 as their secondary diagnosis in their index admission and as their primary or
secondary diagnoses during their 90-day readmissions. Total SSI burden was as-
sessed by evaluating differences in length of stay (LOS) and costs relative to those
with no SSI in the 3 groups: 1) during the initial admission in patients developing
SSI; 2) during the 90-day post surgery for patients who had developed SSI in their
initial admission; and 3) in patients experiencing SSI in their postoperative period.
Generalized linear models adjusting for age, gender, region and p/a diabetes were
used to compute mean differences and 95% confidence intervals. RESULTS: Pa-
tients in group 1 developing SSI as a complication of TKA incur an additional LOS of
2.4 days (95%CI:2.2-2.6 days) and an extra $6360 costs (95%CI:$4610-$8100). Group 2
patients are at risk of 0.75more downstream readmissions, and incur an average of
0.51 days additional LOS (95%CI:0.17-0.85) and $1,160 additional payments (95%CI:
$130-$2180). Group 3 patients are at risk of 1.3 additional readmissions, and incur
an average additional LOS of 8.2 days (95%CI:8.0-8.4) and $21,830 (95%CI:$21,160-
$22,510) in additional payments. CONCLUSIONS: SSI associated with TKA in-
creases current and downstream burden by a factor of 1.3-8.0 times in terms of
readmission rates and additional LOS and provider payments.
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OBJECTIVES: Solid organ transplants (SOT) are expensive, and much of the cost is
incurred in the first 3 months of care to cover pre-transplant, procurement and pro-
cedural costs, which can reach $200,000 per transplant, and higher with complica-
tions. Delayed graft function (DGF) is a complication affecting 20-40% of kidney trans-
plants and is believed to result from ischemic reperfusion injury (IRI). The objective of
this analysis is to quantify the additional charges and length of stay (LOS) associated
with complications such as DGF. METHODS: Using 2008 Health Care Utilization
Project (HCUP) data, individuals with a recorded transplant procedure (ICD-9 CM:
07.94 (thymus); 33.50-33.52 (lung); 336 (heart-lung); 41.94 (spleen); 46.97 (intestine);
50.51 and 50.59 (liver); 52.80-52.83 (pancreas); 65.92 (ovary) were identified. The
mean hospital charges for individuals with and without a recorded complication
diagnosis (ICD-9 CM 996.80-996.89 and additionally for kidney patients a recorded
dialysis procedure 39.95) were compared using student’s t-test. RESULTS: The
number of SOTs (and complications) for eachorgan typewere: 4119 (21%) kidney, 1677
(17%) liver, 485 (28%) heart, and 264 (35%) lung. Heart-lung, intestine, pancreas and
spleenwere excluded from the analysis with100 transplants each. Kidney and liver
transplant patients with complications had significantly higher mean hospital
charges and LOS than thosewithout the complications: kidney ($209,503 vs. $160,997,
p0.001) and (7.0daysvs. 11.1days, p0.001), and liver ($460,351vs. $340,296, p0.001)
and (21.0 days vs. 31.6 days). Heart and Lung transplant patients had higher charges
than those without the complication diagnosis. The difference was not statistically
significant. CONCLUSIONS: Our results demonstrate that having to treat complica-
tions of transplants adds significantly to the cost of hospital care and LOS. There is
a need for a novel agent that may reduce IRI. Proactive management of patients
with risk of IRI may confer substantial savings to hospitals.
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OBJECTIVES: Evaluate the cost of care for patients undergoing posterolateral spinal
fusion (PLF) between on-label Si-CaP use and off-label rhBMP-2 use. It is hypothe-
sized that Si-CaP patients will have lower Total patient costs (cost of entire inpa-
tient hospitalization), lower supply costs, and lower Operating Room costs.
METHODS: Patients over age 18 having a PLF procedure (ICD9 codes 81.62, 81.63, or
81.64) and receiving Si-CaP or rhBMP-2 on day of procedure between January, 2006
and December 31, 2010 were selected. Comorbidities were identified using a mod-
ified Charlsonmethod. Patients with 9 ormore levels fused were excluded. Univar-
iate group comparisons weremade using chi-square and student t-tests. Multivar-
iate linear models were developed using both normal and log transformation.
Discharges with costs less than $1,000 or greater than $500,000 were excluded in
the normal multivariate models but were included in the log transformed models.
RESULTS: A total of 60,260 patients were initially identified. After applying exclu-
sion criteria 59,229 patients were available for analysis (98.3%). Univariate compar-
isons of Total Cost as well as OR and Supply costs were significantly lower for the
Si-CaP cohort (p  0.05). Adjusting for patient and hospital covariates also showed
statistically significant lower estimated mean costs for Si-CaP for all outcomes (p
0.001). Differences in estimatedmeans for Total Costswere lower for Si-CaP $8931
and $7582 using normal and log-transformed values respectively. Estimatedmeans
for Supply Costs showed similar results of $7255 and $5274 for normal and log-
transformed values respectively. Operating RoomCostswere also similar, $961 and
$809. CONCLUSIONS: After adjusting for patient and hospital covariates Si-CaP
patients had significantly lower Total Patient Costs. While Supply Costs showed
similar results they do not fully explain the reduction in Total Cost suggesting that
there are other cost advantages besides product acquisition cost. Further research
should consider cost of complications and readmission.
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OBJECTIVES: The objective of this study was to compare costs and resource utili-
zation in prostate surgery patients with perioperative blood loss (PBL) to those who
did not experience perioperative blood loss (NPBL). METHODS: Males with inpa-
tient prostate surgery discharges (ICD-9-CM: 60.0, 60.12, 60.14, 60.15, 60.3, 60.5,
60.6X, 60.72, 60.73, 60.79, 60.8X, 60.93, 60.94) were identified from the Premier Per-
spective® Database (CY 2009 - Q2 of CY 2010). Discharges were categorized into the
PBL group if they had received at least one blood transfusion (ICD-9-CM: 99.02-
99.07; CPT: 36430, 35455) during the hospital stay, otherwise were included in the
NPBL group. Blood transfusionwas assumed to be an indicator for PBL. Groupswere
matched (1:1) on age, race and APR-DRG severity using propensity scores. Adjusted
estimates for costs (total and departmental), days of stay in hospital (LOS), ICU, and
operating room (OR) time in minutes were compared between the PBL and NPBL
groups using generalized linearmodel (GLM)with gamma distribution and log link.
RESULTS: A total of 18,681prostate surgery discharges were identified. Of those,
1176 (6.3%) required at least one blood transfusion perioperatively. Aftermatching,
1168 discharges were retained in each group for the final analysis. Adjusted mean
total costs were significantly higher for the PBL group compared to NPBL group
($16,757 vs. $12,712, p0.0001). Mean adjusted costs associated with room& board,
surgery and pharmacy between PBL and NPBL group and were also significantly
higher for the PBL group (all p0.05). Compared to the NPBL group, the PBL group
had higher mean LOS (5.8 days vs. 3.6 days), and longer OR time (232 minutes vs.
211 minutes) (both p0.05). CONCLUSIONS: Perioperative blood loss for prostate
surgery patients adds significant burden to hospital costs and resources. Adopting
strategies aimed at minimizing PBL during prostate surgery process may conserve
valuable medical resources.
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OBJECTIVES: The objective of this study was to compare costs and resource utili-
zation in renal surgery patientswith perioperative blood loss (PBL) to thosewho did
not experience perioperative blood loss (NPBL).METHODS: Inpatient discharges for
renal surgery (ICD-9-CM:55.0X, 55.1X, 55.24, 55.3X-55.8X) were identified from the
Premier Perspective® Database (CY 2009-Q2 of CY 2010). Discharges were catego-
rized as PBL group if they had received at least one blood transfusion (ICD-9-CM:
99.02-99.07; CPT:36430, 35455) during the hospital stay, otherwise were included in
the NPBL group. Blood transfusion was assumed to be an indicator for PBL. Groups
were matched (1:1) on age, gender, race, CCI score, APR-DRG severity and elective
admission type using propensity score. Adjusted estimates for costs (total and
departmental), days of stay in hospital (LOS), ICU, and operating room (OR) time in
minutes were compared between PBL and NPBL groups using generalized linear
model (GLM)with gammadistribution and log link. RESULTS:A total of 27,573 renal
surgery discharges were identified. 4,885 (17.7%) of all the selected patients re-
quired at least one blood transfusion perioperatively. After matching, 4,699 dis-
chargeswere retained in each group for the final analysis. Adjustedmean total cost
were significantly higher for the PBL group compared to NPBL group ($48,583 vs.
$35,298, p0.0001). Mean adjusted costs associated with room & board, central
supply, surgery, pharmacy and laboratory and pathology between PBL and NPBL
group and were also significantly higher for PBL group (all p0.05). Compared to
NPBL group, PBL group had higher mean LOS (10.5 days vs. 7.9 days) and ICU days
(4.5 days vs. 3.6 days) and had longer OR time (227 minutes vs. 194 minutes) (all
p0.0001). CONCLUSIONS: Perioperative blood loss for renal surgery patients adds
significant burden to hospital costs and resources. Adopting strategies aimed at
minimizing perioperative blood loss during renal surgeries may be helpful.
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OBJECTIVES: Both Low Anterior Resection (LAR) and Abdominoperineal Resection
(APR) procedures are utilized to treat rectal tumors. There may be occasions when
methods or devicesmay be utilized that could preserve communication to the anus
and avoid conversion of an LAR to APR. We seek to compare the costs of LAR and
APR procedures in comparable patient populations. METHODS: The Premier Per-
spective™ Database (PPD) was used to estimate the incidence and costs of LAR
versus APR in the United States. PPD is the largest hospital-based, database in the
USA providing detailed resource utilization and cost data categorized under a pa-
tients’ principal and secondary diagnosis procedure codes. Patientswith procedure
code for LAR or APR procedures between January 1, 2009 to June 30, 2010 were
selected. RESULTS: A total of 7999 patients with a procedure code for either LAR or
APR were identified between January 1, 2009 and June 30, 2010. APR was used in
1991 (25%) patients and LAR in 6008 (75%) patients. Propensity score methodology
was used to match LAR patients to APR patients based on patient’s demographics
and hospital characteristics. Mean cost per discharge was significantly higher in
APR procedures compared to LAR procedures, $24,922 versus $21,709, respectively,
p0.0004.OR timewasapproximately 54minutes shorter for patientsundergoing LAR
compared to patientswithAPRprocedures, 250minutes vs. 304minutes, respectively,
(p0.001). Patients undergoing LAR procedures had a significantly shorter hospital
length of stay, compared to patients who underwent APR procedures, 9 days versus
10.4 days, respectively, p0.001. CONCLUSIONS: LAR procedures were associated
with shorter hospital lengths of stay, lower OR time and lower mean costs when
compared to a matched set of patients undergoing APR procedures. These observa-
tions highlight the potential cost advantages of further developingmethods or instru-
mentation that would preserve anal function and avoid an APR.
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OBJECTIVES: Bariatric surgical procedure volumes have increased as more hospi-
tals offer the service. Strictures following bariatric surgery using circular staplers
are a common complication. The objective was to assess the cost of gastrointesti-
nal strictures following laparoscopic bariatric surgery that employed circular sur-
gical staplers in the index procedure. METHODS: Laparoscopic bariatric surgery
inpatient discharges (ICD-9-CM:44.31, 44.39) withmention of circular staplers were
identified in the Premier Perspective® Database for CY2008 and CY2009. Esopha-
geal balloon dilation procedure codes (CPT:43235, 43245; ICD-9-CM:44.22) for inpa-
tient and outpatient discharges were used to identify single or multiple strictures
within 6 months following bariatric surgery. Groups were propensity score
matched (1:1) on age, gender, race, region, hospital teaching status and APR-DRG
severity. The initial bariatric surgery costs, hospital length of stay (LOS) and oper-
ating room (OR) time between the stricture and no-stricture groupswere compared
between thematched groups. The cost of strictureswas assessed for patients in the
stricture group. RESULTS:A total of 4,731 laparoscopic bariatric surgery discharges
utilizing circular staplers were identified. 201(4.3%) of these had a mention of at
least one balloon dilation procedure within 6 months of the index procedure. 170
(84.6%) and 31(15.4%) were performed in outpatient and inpatient settings, respec-
tively. 200 patients were propensity matched between the stricture and no-stric-
ture groups. There were no significant differences in initial bariatric surgery costs,
LOS and OR time between groups .For the outpatient setting; mean total costs of 1st
(N169), 2nd (N29), 3rd (N7) and the 4th stricture (N3) were $1251, $1025, $1603
and $1610 respectively. One patient had more than 4 strictures. For the inpatient
setting, mean total cost was $7110 for the 1st (N31) stricture. CONCLUSIONS: Post
surgical strictures can increase treatment costs for laparoscopic bariatric surgery
patients utilizing circular staplers.
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OBJECTIVES: To compare demographics, clinical characteristics, and healthcare
costs and utilization between patients receiving total knee replacement (TKR) with
and without muscle atrophy/weakness (MAW).METHODS:Medical and Pharmacy
claims from a U.S. population with commercial or Medicare supplemental insur-
ance were analyzed to select patients aged 50 receiving TKR (first hospitalization
as the index stay) between January 1, 2006-September 30, 2009. Three cohorts were
constructed: patients with MAW medical claims in 1 year before the index stay
(pre-MAW), patients with first MAW claim during or within the 12-month after the
index stay (post-MAW), and patients without any MAW claim (no-MAW). Baseline
demographic and clinical characteristics, and health care costs and utilization
during 1 year prior to and after the index stay were assessed. Multivariate regres-
sion analyses were performed to compare health care costs incurred within 1 year
after the index stay between cohorts. RESULTS: There were 46,058 Medicare (pre-
MAW: 508; post-MAW: 1,939; no-MAW: 43,611) and 53,696 commercially-insured (pre-
MAW: 470; post-MAW: 2,742; no-MAW: 50,484) patients included in this study. Pre-
MAW patients were more likely to have any hospitalizations (Medicare: 35.4% vs.
15.7% vs. 13.2%; commercial: 24.9% vs. 10.4% vs. 9.1%) during the 1 year pre-index stay
than those in the post-MAW and no-MAW cohorts (all P0.05). The average annual
health care costs for Medicare patients before the index stay were $25,335 (standard
deviation [SD]: 30,047), $15,039 (SD: 21,357), and $12,547 (SD: 19,807) for pre-MAW,
post-MAW, and no-MAWcohorts, respectively, and the numbers for the commercial-
ly-insured patientswere $27,571 (SD: 32,761), and $13,131 (SD: 17,512) and $12,602 (SD:
17,786). Adjusting for demographic and clinical characteristics, both pre-MAW and
post-MAW cohorts had significantly higher total health care costs (Medicare: $4,201
and$9,404; commercial: $2,737 and$66,640) than theno-MAWcohort (all p0.01) over
the 12-month post-index stay.CONCLUSIONS: PatientswithMAWhadhigher health
care costs after TKR than patients without.
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OBJECTIVES: Video-assisted thoracic surgery (VATS) is an emerging alternative for
selected non-small cell lung cancer (NSCLC) patients. In this cost-effectiveness
analysis, we used patient-level data to compare VATS and open surgery for newly
diagnosed stage I NSCLC patients. METHODS: Using information from the cancer
registry, mortality data, and claims data in the Collaboration Center of Health
Information Application database in Taiwan, we identified patients with newly
diagnosed stage I NSCLC received primary lung resection in 2007 and defined the
index date as the date of admission for the index surgery. We compared the cost,
effectiveness, and cost-effectiveness of VATS vs. open surgery within 1 year after
the index date in this retrospective cohort study. The study was conducted from a
payor’s (i.e.,Taiwanese National Health Insurance Program) perspective. All costs
were converted to 2011 US dollars using the local consumer price index and pur-
chasing power parity. We included patient sociodemographics factors, provider
characteristics, and clinical variables as explanatory variables. We used the pro-
pensity score bin bootstrappingmethod for 1000 times to obtain the distribution of
the incremental cost-effectiveness ratio (ICER, in US dollars/life-years (USD/LY))
and to get a better matching of case vs. control by using the above explanatory
variables. RESULTS: We identified 329 patients with newly diagnosis NSCLC; 114
patients received VATS. VATS is associated with higher mean effectiveness (0.972
vs. 0.965 LY) and higher cost ($19,679 vs. $18,996 USD). The estimated mean ICER
was $765,19/LY, and the probability that VATS is more cost-effective at $50,000-
100,000/LY is 41-56%. CONCLUSIONS: This short-term CEA suggested that for
newly diagnosed stage I NSCLC patients VATS is likely to be cost-effective when
compared to open surgery. The result should be interpreted with caution because
of potential endogeneity in treatment selection, and the small absolute difference
and wide confidence interval observed in our data.
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OBJECTIVES: Cystic fibrosis (CF) is a chronic, progressive and recessive genetic
disorder affecting one in every 2000 newborns. A frequent and life threatening
complication reported in patientswith CF is ‘Pneumothorax’ and is associatedwith
significant economic burden. Chest tube drainage, Thoracotomy, and Thoracoscoy
are the choice of treatment for pneumothorax in patients with CF. The objective of
this study was to determine the cost-effectiveness of Thoracoscopic Pleural Abra-
sion (TPA) and Thoracoscopic Talcage (TT) for treatment of pneumothorax in pa-
tients with CF. METHODS: Cost-effectiveness analysis was conducted using effi-
cacy data and costs associated with adverse events (ADE) obtained from literature
review including clinical trials and meta-analysis studies. Direct medical costs
included cost of procedures, hospitalization and those associated with ADEs. All
costs were obtained for a period of one year from US third party perspective and
adjusted to 2011 USD using consumer price index. Effectiveness operationalized as
success rate (no recurrence within one year) was evaluated by developing a deci-
sion tree model using TreeAge Pro 2009. One way sensitivity analysis was per-
formed onADE and total cost for each therapy. Incremental cost-effectiveness ratio
(ICER) was computed to compare procedures. RESULTS: Success rate over one year
periodwas found 91.9% for TPA and 95% for TT. Total cost of treatment for TPA and
TT was found to be $2535 and $3614, respectively. The expected cost of treatment
per unit change for TPA was $27.58 while that of TT was $38.04. An ICER demon-
strated TT ($3614) to be more costly than TPA ($2535). Sensitivity analyses per-
formed were robust to the results. CONCLUSIONS: Thoracoscopic Pleaural Aabra-
sion was more cost-effective than Thoracoscopic Talcage for treatment of
pneumothorax in patients with CF, from US third party perspective in our study.
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OBJECTIVES: Perform a cost-effectiveness analysis to evaluate laparoscopic roux-
en-y gastric bypass(LRYGB) and banding procedures(LAGB) against each other and
no treatment. METHODS: A backwards induction cost-effectiveness model was
utilized and analysis was conducted from a societal perspective. Lifetime costs and
life expectancies for LRYGB, LAGBmorbidly obese patientswere compared to those
on no treatment and to each other. Efficacy and probabilities estimates were ob-
tained from a literature review. Costs and quality-adjusted life years(QALYs) were
discounted by a 3% annual rate, and costs are reported in 2011 US dollars. A one-
way sensitivity analyses was done to assess the model’s robustness. RESULTS:
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